Table 4 Logarithm of anti-CSP IgG antibody titres pre- and post-vaccination in each year in children who received RTS,S/AS01E vaccine for both countries (Burkina Faso and Mali), measured using the two assays: - GSK ELISA and Oxford MSD assay
Time of Sample Collection | N | Log GMT, EU/ml (95% CI) | Number with 2-fold Increase in titre (%) | Number with 10-fold increase in titre (%) |
|---|---|---|---|---|
GSK ELISA (Total N = 1484) | ||||
Pre-2017a | 201 | |||
Post-2017 | 198 | 5.9 (5.8–6.1) | 194/197 (98.5) | 194/197 (98.5) |
Pre-2018 | 279 | 3.6 (3.5–3.8) | ||
Post-2018 | 279 | 5.5 (5.4–5.6) | 247/279 (88.5) | 76/279 (27.2) |
Pre-2019 | 291 | 3.8 (3.7–3.9) | ||
Post-2019 | 291 | 5.1 (5–5.2) | 246/291 (84.5) | 31/291 (10.7) |
Pre-2020 | 327 | 3.6 (3.5–3.7) | ||
Post-2020 | 327 | 4.9 (4.8–4.9) | 265/327 (81) | 25/327 (7.6) |
Pre-2021 | 385 | 3.6 (3.5–3.7) | ||
Post-2021 | 381 | 4.8 (4.7–4.9) | 299/381 (78.5) | 16/381 (4.2) |
OXFORD MSD ASSAY (Total N = 502) | ||||
Pre-2017 | 104 | 5.2 (5.1–5.3) | ||
Post-2017 | 114 | 12.1 (11.8–12.3) | 109/114 (95.6) | 101/114 (88.6) |
Pre-2018 | 99 | 9.1 (8.8–9.5) | ||
Post-2018 | 100 | 11.8 (11.5–12) | 97/100 (97) | 51/100 (51) |
Pre-2019 | 100 | 9.8 (9.6–10.0) | ||
Post-2019 | 100 | 11.2 (11–11.4) | 77/100 (77) | 16/100 (16) |
Pre-2020 | 99 | 9.3 (9.10–9.50) | ||
Post-2020 | 99 | 10.3 (10.1–10.5) | 64/99 (64.6) | 4/99 (4) |
Pre-2021 | 100 | 9.7 (9.4–10.0) | ||
Post-2021 | 100 | 10.4 (10.2–10.6) | 50/100 (50) | 4/100 (4) |
